Clinical TrialJun 30, 2026, 09:11 AM
AC Immune Reports Interim 12-Month Data from ACI-24 ABATE Trial
AI Summary
AC Immune SA announced interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer’s disease. The anti-Abeta active immunotherapy was generally safe and well tolerated in the first three cohorts, showing anti-Abeta antibody dose-response without evidence of ARIA-E. However, the company noted a need to further enhance immunogenicity, leading to the initiation of an AD4 cohort testing an additional adjuvant. AC Immune has an exclusive agreement with Takeda, under which it has received $112 million to date and is eligible for up to $2.1 billion in additional milestones and royalties.
Key Highlights
- ACI-24 anti-Abeta active immunotherapy was generally safe and well tolerated in first three AD cohorts (AD1-3) of ABATE trial.
- No evidence of amyloid-related imaging abnormalities-edema (ARIA-E) observed in the trial to date.
- Anti-Abeta antibody dose-response was demonstrated with antibodies detected at all dose levels in cohorts AD1-3.
- Ongoing AD4 cohort includes an additional adjuvant designed to enhance ACI-24 responses.
- AC Immune received a $100 million upfront payment and a $12 million milestone from Takeda.
- AC Immune is eligible for up to approximately $2.1 billion in additional potential milestones and tiered double-digit royalties from Takeda.
Price Impact
More from ACIU